Resources Repository
-
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Priority Setting/Ethics | Health/Medicine | Health Systems | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Asia & Pacific | Oceania -
ArticlePublication 2021Correct COVID-19 Vaccine Misinformation: Lancet Commission on COVID-19 Vaccines & Therapeutics Task Force Members
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 …
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 vaccines. In 2020, up to one-third or more of people surveyed both globally and in the U.S. indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted.…
Preferences/Values | Health/Medicine | Global Governance | Infectious Diseases | Social Determinants | Policy/Regulation | Culture/Society | Science/Technology | Global -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Priority Setting/Ethics | Health/Medicine | Health Systems | Health Outcomes | Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Policy/Regulation | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Ethiopian Health Decision Sciences
This resource pack provides a curated set of peer-reviewed articles that represent the growing evidence …
This resource pack provides a curated set of peer-reviewed articles that represent the growing evidence base for decision making and priority setting in Ethiopia - with an emphasis on improving health, reducing inequity, and preventing health-related impoverishment. Curated by Dr. Stéphane Verguet at the Center for Health Decision Science, most of the papers reflect work done as part of the Disease Control Priorities-Ethiopia (DCP-E) project. The pack provides scholarship that spans maternal-child health, vaccine-preventable disease, infectious…
Priority Setting/Ethics | Health/Medicine | Health Systems | Costing Methods | Health Outcomes | Mathematical Models | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Sub-Saharan Africa | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2020Translating Population Evidence to Individual Patients
In this paper, the authors describe the differences in population level outcomes compared to individual …
In this paper, the authors describe the differences in population level outcomes compared to individual patients and discuss ways that these are differences. The authors cover topics including the difference between relative and absolute risk and benefit. They use an example of the decision to start anticoagulation in new-onset atrial fibrillation to discuss translating population level evidence to treatment of an individual. These options include generalizability, subgroup analysis, prediction rules, following response to therapy, and even…
Test Performance | Health/Medicine | Health Systems | Evidence Synthesis | Clinical Care -
ArticlePublication 2020Who Benefits Most from Extending Financial Protection for Cataract Surgery in Vietnam?: An ECEA
This study evaluated the potential impact, on health and financial protection, of eliminating medical and …
This study evaluated the potential impact, on health and financial protection, of eliminating medical and non-medical out-of-pocket costs associated with cataract surgery in Vietnam using extended cost-effectiveness analysis.
Priority Setting/Ethics | Health/Medicine | Health Systems | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Asia & Pacific -
ArticlePublication 2020Health Gains & Financial Risk Protection Afforded by Public Financing of Selected Malaria Interventions in Ethiopia: An ECEA
This article, published in the Malaria Journal, aims to estimate the expected health and financial …
This article, published in the Malaria Journal, aims to estimate the expected health and financial risk protection (FRP) benefits of universal public financing of key malaria interventions in Ethiopia. An extended cost-effectiveness analysis (ECEA) is used to estimate the potential health and FRP benefits of publicly financing a 10% increase in artemisinin-based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and a hypothetical malaria vaccine. The results indicate that ACT, LLIN,…
Priority Setting/Ethics | Health/Medicine | Health Systems | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Sub-Saharan Africa -
ArticlePublication 2017Catastrophic Costs Potentially Averted by TB Control in India and South Africa
This study estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis …
This study estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. The authors investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis…
Priority Setting/Ethics | Health/Medicine | Health Systems | Mathematical Models | Infectious Diseases | Economics/Finance | Sub-Saharan Africa | Asia & Pacific -
ArticlePublication 2019Health and Financial Benefits of Averting Malaria in Zambia: An ECEA
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout …
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout of the malaria vaccine RTS,S/AS01 in Zambia on the health benefits of children under five, and financial benefits on their households. The authors assumed a three-dose vaccination schedule (over 6-9 months), and vaccine cost of US$5 per dose. To assess vaccine impact, for each income quintile, they computed the number of under-five malaria deaths prevented, the household out-of-pocket (OOP) malaria-related…
Priority Setting/Ethics | Health/Medicine | Health Systems | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Sub-Saharan Africa